Search - tctmd.com

Displaying 1 - 20 of 141

Sort: Relevancy | Date

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

News Conference News ISC 2026

OCEANIC-STROKE: Asundexian Prevents Recurrent Strokes, With No Added Bleeding

February 09, 2026

TCTMD’s Top 10 Most Popular Stories for November 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

December 01, 2025

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

News Daily News

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

October 09, 2025

No Clear Risk of Dementia After TIA: Framingham Heart Study

News Daily News

No Clear Risk of Dementia After TIA: Framingham Heart Study

July 10, 2025

ASSET-IT: Tirofiban Boosts Outcomes After IV Thrombolysis for Acute Stroke

News Conference News ESOC 2025

ASSET-IT: Tirofiban Boosts Outcomes After IV Thrombolysis for Acute Stroke

May 27, 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

March 12, 2025

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

Scientific Statement Reviews Current Antithrombotic Options in PAD

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

August 26, 2024

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

News Daily News

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

August 21, 2024

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

August 19, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

‘Landmark Moment’ for Middle Meningeal Artery Embolization for Subdural Hematoma

News Conference News ISC 2024

‘Landmark Moment’ for Middle Meningeal Artery Embolization for Subdural Hematoma

February 16, 2024

MOST: Eptifibatide, Argatroban Don’t Improve on IV Thrombolysis Alone

News Conference News ISC 2024

MOST: Eptifibatide, Argatroban Don’t Improve on IV Thrombolysis Alone

February 08, 2024

DAPT Works When Started Up to 3 Days After Mild Stroke, TIA

News Daily News

DAPT Works When Started Up to 3 Days After Mild Stroke, TIA

January 04, 2024

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.